

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**UNAUDITED FINANCIAL INFORMATION OF
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH (GROUP) CO., LTD.
FOR THE TWELVE MONTHS ENDED 31 DECEMBER 2023**

Set out below is the key unaudited financial information of Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (“EV MedTech”) for the twelve months ended 31 December 2023. EV MedTech is owned as to 40.32% by the Company and its results are consolidated with the financial statements of the Company. The shares of EV MedTech are listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange.

	For the twelve months ended 31 December 2023 RMB'000	For the twelve months ended 31 December 2022 RMB'000	Change %
Revenue	1,187,204.5	896,500.4	32.43
Profit	572,267.0	413,895.4	38.26
Net profit attributable to equity owners of EV MedTech	492,432.0	356,878.5	37.98
	As of 31 December 2023 RMB'000	As of 31 December 2022 RMB'000	Change %
Total assets	4,242,072.4	1,995,118.7	112.62
Total equity attributable to equity owners of EV MedTech	3,843,816.2	1,718,668.3	123.65

Shareholders and investors are reminded that the financial information above was prepared in accordance with PRC accounting standards and are limited solely to the operation of EV MedTech and are unrelated to the other subsidiaries of the Group. Such information is unaudited, and does not (a) exclude intra-group transactions, (b) include all the business of the Group, and (c) represent or provide a full picture of the operation or status of the Group. **Shareholders and potential investors of the Company are reminded to exercise caution when dealing in the securities of the Company.**

By order of the Board
MicroPort Scientific Corporation
Dr. Zhaohua Chang
Chairman

Shanghai, the PRC, 23 February 2024

As at the date of this announcement, the executive Director is Dr. Zhaohua Chang; the non-executive Directors of the Company are Mr. Hiroshi Shirafuji, Mr. Norihiro Ashida, Ms. Weiqin Sun, Dr. Qiyi Luo and Mr. Bo Peng; and the independent non-executive Directors of the Company are Mr. Jonathan H. Chou, Dr. Guoen Liu and Mr. Chunyang Shao.

* *For identification purpose only*